Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.PSTV · Entity 7637 | Chief Development Officer | April 20, 2026 | April 22, 2026 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Chief Development Officer | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 20,000 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 20,000 · Balance 20,000 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-04-19 | Direct | 20,000 |
Reported balance
After 2026-04-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-20 · Grant · Acquired 20,000 · Balance 20,000 F2: One fourth of the options vest on April 20, 2027 and an additional 1/36th of the remaining options vest on each monthly anniversary thereafter in substantially equal increments. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments.
F2: One fourth of the options vest on April 20, 2027 and an additional 1/36th of the remaining options vest on each monthly anniversary thereafter in substantially equal increments.
KIORA PHARMACEUTICALS INC
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,741 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Tax withholding · Disposed 929 · Balance 31,741 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 22, 2026 21:00 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193125-26-170730 · ownership.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-04-19 F2 · derivative.exercise_date: One fourth of the options vest on April 20, 2027 and an additional 1/36th of the remaining options vest on each monthly anniversary thereafter in substantially equal increments. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:00 UTC | CERENOME, INC. PSTV · Entity 7637 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-170730 · ownership.xml · derivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:46 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 929 | $1.95 | $1,811.55 |
DisclosureSEC source: 0001372514-26-000032 · wk-form4_1775162772.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,741 Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:37 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 13,067 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001372514-26-000014 · wk-form4_1773175029.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,067 Underlying: Common Stock · 13,067 shares Expires 2036-04-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:37 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 6,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-26-000014 · wk-form4_1773175029.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,670 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 19:03 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | Tax withholdingCommon Stock | 238 | $2.02 | $480.76 |
DisclosureSEC source: 0001372514-26-000007 · wk-form4_1772823830.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,137 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:28 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 15,543 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000035 · wk-form4_1743640133.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,543 Underlying: Common Stock · 15,543 shares Expires 2035-04-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2026, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:28 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 7,772 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-25-000035 · wk-form4_1743640133.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,375 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2026, April 1, 2027 and April 1, 2028, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 14,710 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000094 · wk-form4_1720034173.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,710 Underlying: Common Stock · 14,710 shares Expires 2034-07-01 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 1, 2025, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:16 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 7,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-24-000094 · wk-form4_1720034173.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,577 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of July 1, 2025, July 1, 2026 and July 1, 2027, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 19:40 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | PurchaseCommon Stock | 1,431 | $5.29 | $7,569.99 |
DisclosureSEC source: 0001372514-24-000063 · wk-form4_1718394015.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,222 Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:48 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000149 · wk-form4_1696366080.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-09-29 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to twenty-five percent (25%) of the shares underlying the Option upon grant on September 29, 2023, twenty-five percent (25%) on September 29, 2024 and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:48 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-23-000149 · wk-form4_1696366080.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,338 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to twenty-five percent (25%) of the shares immediately upon grant, and twenty-five percent (25%) on each of September 29, 2024, September 29, 2025 and September 29, 2026, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:14 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 10,400 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000034 · wf-form4_167823807843002.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2033-03-03 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 3, 2024, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:14 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001372514-23-000034 · wf-form4_167823807843002.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,838 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of March 3, 2024, March 3, 2025 and March 3, 2026, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 21:34 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001104659-22-111246 · tm2228925-3_4seq1.xml · derivative · entry 2 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-10-21 F2 · derivative.exercise_date: The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 21:34 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-111246 · tm2228925-3_4seq1.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,238 F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of October 21, 2023, October 21, 2024 and October 21, 2025, subject to the reporting person's continuous service through each such vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:03 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011493 · tm225348d4_4.xml · derivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| October 21, 2021 Filed Nov 10, 2021 21:17 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001104659-21-136953 · tm2132572-1_4seq1.xml · derivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-10-21 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| October 21, 2021 Filed Nov 22, 2021 21:31 UTC Amendment | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantCommon Stock | 9,520 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142530 · tm2133588-2_4a.xml · nonDerivative · entry 1 Daniels Eric Joseph · CIK 0001892943 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,520 F1 · shares: These shares were omitted from the Reporting Person's Form 4 filed on November 10, 2021. F2 · price: Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.